Video

Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

Author(s):

Ruben Mesa, M.D.,Rami S. Komrokji, M.D.

Expert perspectives on the possible adverse events patients may encounter while receiving treatment for myeloproliferative neoplasms.

Related Videos
A panel of 3 experts on CML
Related Content
FDA approves Ryoncil for children with GVHD.
December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Image of blood test.
December 8th 2024

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

Morgan Bayer
Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Illustration of blood cells.
November 4th 2024

Jakafi, Pegasys Combination Beneficial in Newly Diagnosed Polycythemia Vera

Alex Biese
Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, research showed.
Illustration of bone marrow.
October 31st 2024

Inrebic May Reduce Spleen Volume in Myelofibrosis

Alex Biese
Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.